重组人血管内皮抑制素联合新辅助化疗对晚期胃癌患者的影响

扫码查看

原文链接

万方数据
维普

中文摘要：目的:探讨针对晚期胃癌(AGC)患者实施重组人血管内皮抑制素联合新辅助化疗的影响。方法:选择2020年5 月—2022 年 3 月临沂市中医院收治的 74 例AGC患者，按随机数表法分为两组。对照组(37 例)采取新辅助化疗(奥沙利铂+替吉奥)，观察组(37 例)在对照组基础上采取重组人血管内皮抑制素治疗。比较两组短期疗效、血清肿瘤标志物水平[癌胚抗原(CEA)、糖链抗原 199(CA199)及癌抗原 724(CA724)]、循环肿瘤细胞(CTC)水平、生存情况及不良反应。结果:观察组客观有效率(ORR)为 56。76%，高于对照组的 29。73%，观察组疾病控制率(DCR)为 86。49%，高于对照组的 62。16%，差异有统计学意义(P<0。05)。治疗后，两组CEA、CA199、CA724、CTC水平均低于治疗前，且观察组低于对照组，差异有统计学意义(P<0。05)。随访 1 年的结果显示，与对照组相比，观察组复发/远处转移率较低，无病生存率较高，总生存率较高，差异有统计学意义(P<0。05)。两组用药期间不良反应总发生率比较，差异无统计学意义(P>0。05)。结论:针对AGC患者实施重组人血管内皮抑制素联合新辅助化疗，短期内疗效确切，可降低肿瘤标志物水平与CTC水平，延长生存期，且安全性良好。

外文标题：The Effect of Recombinant Human Endostatin Combined with Neoadjuvant Chemotherapy on Advanced Gastric Cancer Patients

外文摘要：Objective:To explore the effect of implementing Recombinant Human Endostatin combined with neoadjuvant chemotherapy for patients with advanced gastric cancer(AGC).Method:A total of 74 AGC patients admitted to Linyi Traditional Chinese Medicine Hospital from May 2020 to March 2022 were randomly divided into two groups using a random number table method.The control group(37 cases)received neoadjuvant chemotherapy(Oxaliplatin+Tegafur,Gimeracil and Oteracil Potassium),while the observation group(37 cases)received Recombinant Human Endostatin treatment on the basis of the control group.The short-term efficacy,serum tumor marker levels[carcinoembryonic antigen(CEA),glycan antigen 199(CA199),and cancer antigen 724(CA724)],circulating tumor cell(CTC)levels,survival,and adverse reactions were compared between two groups.Result:The objective effective rate(ORR)of the observation group was 56.76%,which was higher than 29.73%of the control group,and the disease control rate(DCR)of the observation group was 86.49%,which was higher than 62.16%of the control group,the differences were statistically significant(P<0.05).After treatment,CEA,CA199,CA724 and CTC levels in both groups were lower than those before treatment,and those in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).The results of 1-year follow-up showed that compared with the control group,the recurrence/distant metastasis rate in the observation group was lower,the disease-free survival rate was higher,and the overall survival rate was higher,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Implementing Recombinant Human Endostatin combined with neoadjuvant chemotherapy for AGC patients has a definite short-term therapeutic effect,can reduce tumor marker and CTC levels,prolong survival,and is safe.

外文关键词：

Advanced gastric cancerRecombinant Human EndostatinNeoadjuvant chemotherapyTumor markers

作者：

牟伟

展开 >

作者单位：

临沂市中医医院山东临沂 276000

关键词：

晚期胃癌重组人血管内皮抑制素新辅助化疗肿瘤标志物

出版年：

2024

DOI：